Fiscal Q2 2023 revenue totaled $12 million
Sprout revenue totaled $8.4 million, an increase of 19%
year-over-year
Reported gross profit margin was 9.2% for
fiscal second quarter
Company sets goal of achieving positive
Adjusted EBITDA1 by end of fiscal 2025
Company will host a conference call today
at 4:15 p.m. (Eastern Time) Friday,
December 16, 2022, to discuss these results
LAVAL,
QC, Dec. 16, 2022 /PRNewswire/ - Neptune
Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:
NEPT), a consumer-packaged goods company focused on plant-based,
sustainable and purpose-driven lifestyle brands, today announced
its financial and operating results for the three-month period
ending September 30, 2022.
Neptune recorded second quarter revenue of $12 million driven largely by Sprout, our organic
children's food brand, which consistently shows revenue growth
year-over-year and today remains a top five organic baby food brand
currently outperforming the category in sales growth. In
nutraceutical products, Biodroga achieved $3.2 million in revenue in the second quarter of
fiscal 2023, a decline of 22% from the quarter ended September 30, 2021, primarily due to shipment
timing.
Despite having mostly exited the cannabis business in the second
fiscal quarter (the sale of the cannabis assets was closed on
November 9, 2022) the Company saw
only a small reduction in sales due to the strong performance of
Sprout, up 19% year-over-year.
Second Quarter 2023 Financial Highlights:
- Net sales for the fiscal second quarter 2023 revenue totaled
$12 million, down from $12.5 million for the same period last year.
- Gross profit in fiscal second quarter of $1.1 million compared to a gross loss of
$(1.2) million for the same period
last year.
- Net loss of $37.3 million for
second quarter compared to a net loss of $12.1 million in the prior comparable period in
fiscal 2022.
- Gross profit margin of 9.2% for fiscal second quarter compared
to (9.4)% for the same period last year.
Second Quarter Events and Business Highlights:
- Post quarter end, completed the divestiture of the cannabis
assets, including the Sherbrooke
plant and the Mood Ring and PanHash brands.
- Announced amendment and expansion of Sprout secured promissory
notes led by Morgan Stanley to expand the facility from
US$22.5 million to a maximum of
US$37.5 million and additional notes
received of $3.25 million in the
second quarter.
- Sprout Organics distribution coverage increased to 90%.
- Organic children's food products in 27,337 doors vs 19,756
doors a year-ago, a 38% increase.
- Expanded into new product categories into Up-Age meals beyond
the Baby Food Aisle.
Conference Call Details:
The Company will host a
conference call at 4:15 p.m. (Eastern Time)
on Friday, December 16, 2022, to discuss these results. The
conference call will be webcast live and can be accessed by
registering on the Events and Presentations portion of Neptune's
Investor Relations website at www.investors.neptunewellness.com.
The webcast will be archived for approximately 90 days.
1. ADJUSTED EBITDA
Although the concept of Adjusted EBITDA is not a financial or
accounting measure defined under US GAAP and it may not be
comparable to other issuers, it is widely used by companies.
Neptune obtains its Adjusted EBITDA measurement by adding to net
loss, net finance costs (income) and depreciation and amortization,
and income tax expense (recovery). Other items such as equity
classified stock-based compensation, non-employee compensation
related to warrants, litigation provisions, business acquisition
and integration costs, signing bonuses, severances and related
costs, impairment losses on non-financial assets, write-downs of
non-financial assets, revaluations of derivatives, system
migration, conversion and implementation, CEO directors and
officers insurance, costs related to conversion from IFRS to US
GAAP and other changes in fair values are also added back. The
exclusion of net finance costs (income) eliminates the impact on
earnings derived from non-operational activities. The exclusion of
depreciation and amortization, stock-based compensation,
non-employee compensation related to warrants, litigation
provisions, impairment losses, write-downs revaluations of
derivatives and other changes in fair values eliminates the
non-cash impact, and the exclusion of acquisition costs,
integration costs, signing bonuses, severance and related costs,
costs related to cybersecurity and costs related to conversion from
IFRS to US GAAP present the results of the on-going business. From
time to time, the Company may exclude additional items if it
believes doing so would result in a more effective analysis of
underlying operating performance. In Q4 2022, the Company added the
costs related to the conversion from IFRS to US GAAP as an
adjustment to the definition of Adjusted EBITDA. Adjusting for
these items does not imply they are non-recurring.
About Neptune Wellness Solutions Inc.
Headquartered in
Laval, Quebec, Neptune is a
consumer-packaged goods company with a mission to redefine health
and wellness. Neptune is focused on building a portfolio of high
quality, affordable consumer products in response to long-term
secular trends and market demand for natural, plant-based,
sustainable and purpose-driven lifestyle brands. The Company
utilizes a highly flexible, cost-efficient manufacturing and supply
chain infrastructure that can be scaled to quickly adapt to
consumer demand and bring new products to market through its mass
retail partners and e-commerce channels. For additional
information, please visit: https://neptunewellness.com/.
Disclaimer – Safe Harbor Forward–Looking
Statements
This news release contains "forward-looking
information" and "forward-looking statements" (collectively,
"forward-looking statements") within the meaning of applicable
securities laws. All statements, other than statements of
historical fact, are forward-looking statements and are based on
expectations, estimates, and projections as at the date of this
news release. Any statement that involves discussions with respect
to predictions, expectations, beliefs, plans, projections,
objectives, assumptions, future events or performance (often but
not always using phrases such as "expects", or "does not expect",
"is expected", "anticipates" or "does not anticipate", "plans",
"budget", "scheduled", "forecasts", "estimates", "believes" or
"intends" or variations of such words and phrases or stating that
certain actions, events or results "may" or "could", "would",
"might" or "will" be taken to occur or be achieved) are not
statements of historical fact and may be forward-looking
statements. In this news release, forward-looking statements
include, among other things, statements with respect to the
Company's strategic review, expected cost savings, projected growth
of Sprout and Biodroga, the success of the Company's
action plan, future increased revenues, expectations regarding
expenses, cash needs, cash flow, liquidity and sources of
funding, future expansion plans, initiatives and strategies of
the Company, and the Company's performance, growth initiatives,
profitability, future product launches and plans and gain in market
share.
These forward-looking statements are based on assumptions and
estimates of management of the Company at the time such statements
were made. Actual future results may differ materially as
forward-looking statements involve known and unknown risks,
uncertainties, and other factors which may cause the actual
results, performance, or achievements of the Company to materially
differ from any future results, performance, or achievements
expressed or implied by such forward-looking statements. Such
factors, among other things, include: the ability of the Company to
successfully implement its strategic initiatives; implications of
the COVID-19 pandemic on the Company's operations; fluctuations in
general macroeconomic conditions; fluctuations in securities
markets; changing consumer habits; the ability of the Company to
successfully achieve its business objectives and cost cutting
plans; plans for expansion; political and social uncertainties;
inability to obtain adequate insurance to cover risks and hazards;
the ability of the Company to obtain financing on acceptable terms,
the adequacy of our capital resources and liquidity, including but
not limited to, availability of sufficient cash flow to execute our
business plan (either within the expected timeframe or at all); the
ability of the Company to obtain financing on acceptable terms,
expectations regarding the resolution of litigation and other legal
and regulatory proceedings, reviews and investigations; employee
relations; and the presence of laws and regulations that may impose
restrictions in the markets where the Company operates. Although
the forward-looking statements contained in this news release are
based upon what management of the Company believes, or believed at
the time, to be reasonable assumptions, the Company cannot assure
shareholders that actual results will be consistent with such
forward-looking statements, as there may be other factors that
cause results not to be as anticipated, estimated or intended.
Readers should not place undue reliance on the forward-looking
statements and information contained in this news release. The
Company assumes no obligation to update the forward-looking
statements of beliefs, opinions, projections, or other factors,
should they change, except as required by law.
Additional information regarding these and other risks and
uncertainties relating to the Company's business are contained
under the heading "Risk Factors" in the Company's Annual Report on
Form 10-K dated July 7, 2022, for the
year ended March 31, 2022.
DISCLOSURE REGARDING FORWARD-LOOKING
STATEMENTS
This Quarterly Report on Form 10-Q ("Quarterly Report" or
"Form 10-Q") contains statements that are, or may be considered to
be, "forward-looking statements." Forward-looking statements are
neither historical facts nor assurances of future performance.
Instead, they are based on current beliefs, expectations or
assumptions regarding the future of the business, future plans and
strategies, operational results and other future conditions. All
statements other than statements of historical fact included in
this Form 10-Q regarding the prospects of Neptune Wellness
Solutions Inc. ("Neptune", the "Company", "we", "us", or "our") the
industry or its prospects, plans, financial position or business
strategy may constitute forward-looking statements. In addition,
forward-looking statements generally can be identified by the use
of forward-looking words such as "plans," "expects" or "does not
expect," "is expected," "look forward to," "budget," "scheduled,"
"estimates," "forecasts," "will continue," "intends," "the intent
of," "have the potential," "anticipates," "does not anticipate,"
"believes," "should," "should not," or variations of such words and
phrases that indicate that certain actions, events or results
"may," "could," "would," "might," or "will," "be taken," "occur,"
or "be achieved," or the negative of these terms or variations of
them or similar terms. Furthermore, forward-looking statements may
be included in various filings that the Company makes with the
Securities and Exchange Commission (the "SEC") or press releases or
oral statements made by or with the approval of one of the
Company's authorized executive officers. Although the Company
believes that the expectations reflected in these forward-looking
statements are reasonable, it cannot assure you that these
expectations will prove to be correct. These forward-looking
statements are subject to certain known and unknown risks and
uncertainties, as well as assumptions that could cause actual
results to differ materially from those reflected in these
forward-looking statements.
By their very nature, forward-looking statements involve
inherent risks and uncertainties, both general and specific, and
risks exist that predictions, forecasts, projections and other
forward-looking statements will not be achieved. The Company
cautions readers not to place undue reliance on these statements as
a number of important factors could cause the actual results to
differ materially from the beliefs, plans, objectives,
expectations, anticipations, estimates and intentions expressed in
such forward-looking statements. Risks, uncertainties and other
factors which may cause the actual results, performance or
achievements of the Company, as applicable, to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking information and
statements include, but are not limited to the risks described in
Item 1A-"Risk Factors" of Part II this Form 10-Q.
Readers are cautioned not to place undue reliance on any
forward-looking statements contained in this Form 10-Q, which
reflect management's opinions only as of the date hereof. Except as
required by law, the Company undertakes no obligation to revise or
publicly release the results of any revision to any forward-looking
statements. You are advised, however, to consult any additional
disclosures the Company makes in its reports to the SEC. All
subsequent written and oral forward-looking statements attributable
to the Company or persons acting on its behalf are expressly
qualified in their entirety by the cautionary statements contained
in this Form 10-Q.
Risks Factors Summary
Set forth below is summary of some of the principal risks
the Company faces:
- our ability to successfully manage our liquidity and
expenses, and continue as a going concern;
- our ability to manage our supply chain
effectively;
- our ability to succeed at implementing cost cutting
initiatives;
- our ability to maintain customer relationships and demand
for our products;
- the impact of current and future substantial litigation,
investigations and proceedings;
- the overall business and economic conditions;
- the potential financial opportunity of our addressable
markets;
- the competitive environment;
- the protection of our current and future intellectual
property rights;
- our ability to recruit and retain the services of our key
personnel;
- our ability to develop commercially viable
products;
- our ability to pursue new business
opportunities;
- our ability to obtain financing on reasonable terms or at
all;
- our ability to integrate our acquisitions and generate
synergies; and
- the impact of new laws and regulations in Canada, the United
States or any other jurisdiction in which we currently do or
intend to do business.
PART I - FINANCIAL
INFORMATION
Item 1. FINANCIAL
STATEMENTS.
Condensed Consolidated Interim Financial Statements
of
(Unaudited)
NEPTUNE WELLNESS SOLUTIONS INC.
For the three and six-month periods ended September 30, 2022 and 2021
NEPTUNE WELLNESS SOLUTIONS INC.
Condensed Consolidated Interim Balance Sheets
(Unaudited) (in U.S. dollars)
|
|
|
As at
|
|
As at
|
|
|
|
September 30,
2022
|
|
March 31,
2022
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
Current
assets:
|
|
|
|
|
|
Cash and cash
equivalents
|
|
|
$1,394,603
|
|
$8,726,341
|
Short-term
investment
|
|
|
17,489
|
|
19,255
|
Trade and other
receivables
|
|
|
4,946,406
|
|
7,599,584
|
Prepaid
expenses
|
|
|
2,876,115
|
|
3,983,427
|
Inventories
|
|
|
15,808,436
|
|
17,059,406
|
Assets held for
sale
|
|
|
3,203,557
|
|
—
|
Total current
assets
|
|
|
28,246,606
|
|
37,388,013
|
|
|
|
|
|
|
Property, plant and
equipment
|
|
|
2,145,027
|
|
21,448,123
|
Operating lease
right-of-use assets
|
|
|
2,474,370
|
|
2,295,263
|
Intangible
assets
|
|
|
17,792,596
|
|
21,655,035
|
Goodwill
|
|
|
14,354,340
|
|
22,168,288
|
Total assets
|
|
|
$65,012,939
|
|
$104,954,722
|
|
|
|
|
|
|
Liabilities and
Equity
|
|
|
|
|
|
|
|
|
|
|
|
Current
liabilities:
|
|
|
|
|
|
Trade and other
payables
|
|
|
$22,960,348
|
|
$22,700,849
|
Current portion of
operating lease liabilities
|
|
|
585,536
|
|
641,698
|
Deferred
revenues
|
|
|
130,464
|
|
285,004
|
Provisions
|
|
|
5,860,704
|
|
1,118,613
|
Liability related to
warrants
|
|
|
2,820,025
|
|
5,570,530
|
Total current
liabilities
|
|
|
32,357,077
|
|
30,316,694
|
|
|
|
|
|
|
Operating lease
liabilities
|
|
|
2,343,311
|
|
2,063,421
|
Loans and
borrowings
|
|
|
14,692,156
|
|
11,648,320
|
Other
liability
|
|
|
24,000
|
|
88,688
|
Total
liabilities
|
|
|
49,416,544
|
|
44,117,123
|
|
|
|
|
|
|
Shareholders'
Equity:
|
|
|
|
|
|
Share capital -
without par value (8,516,894 shares issued and outstanding as
of
September 30, 2022; 5,560,829 shares
issued and outstanding as of March 31, 2022)
|
|
|
321,769,905
|
|
317,051,125
|
Warrants
|
|
|
6,079,890
|
|
6,079,890
|
Additional paid-in
capital
|
|
|
56,306,211
|
|
55,980,367
|
Accumulated other
comprehensive loss
|
|
|
(14,307,804)
|
|
(7,814,163)
|
Deficit
|
|
|
(358,363,505)
|
|
(323,181,697)
|
Total equity
attributable to equity holders of the Company
|
|
|
11,484,697
|
|
48,115,522
|
|
|
|
|
|
|
Non-controlling
interest
|
|
|
4,111,698
|
|
12,722,077
|
Total shareholders'
equity
|
|
|
15,596,395
|
|
60,837,599
|
|
|
|
|
|
|
Commitments and
contingencies
|
|
|
|
|
|
Subsequent
events
|
|
|
|
|
|
Total liabilities and
shareholders' equity
|
|
|
$65,012,939
|
|
$104,954,722
|
On behalf of the
Board:
|
|
|
|
|
|
/s/ Julie Philips
|
|
/s/ Michael Cammarata
|
Julie
Philips
|
|
Michael
Cammarata
|
Chair of the
Board
|
|
President and
CEO
|
NEPTUNE WELLNESS SOLUTIONS INC.
Condensed Consolidated Interim Statements of Loss and
Comprehensive Loss
(Unaudited) (in U.S.
dollars)
|
|
|
|
|
|
|
|
|
|
|
Three-month periods
ended
|
|
Six-month periods
ended
|
|
|
|
|
September 30,
2022
|
|
September 30,
2021
|
|
September 30,
2022
|
|
September 30,
2021
|
|
|
|
|
|
|
|
|
|
|
|
Revenue from sales net
of excise taxes
of $1,600 and $643,476 (2021 - $240,080
and $380,699)
|
|
|
$11,755,056
|
|
$12,309,755
|
|
$27,723,154
|
|
$22,131,395
|
Royalty
revenues
|
|
|
218,731
|
|
188,593
|
|
502,920
|
|
424,660
|
Other
revenues
|
|
|
13,055
|
|
20,283
|
|
32,996
|
|
41,085
|
Total
revenues
|
|
|
11,986,842
|
|
12,518,631
|
|
28,259,070
|
|
22,597,140
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales other
than impairment loss on inventories,
net of subsidies of nil and nil (2021 -
$269,210 and $931,705)
|
|
|
(10,878,974)
|
|
(10,681,881)
|
|
(26,965,552)
|
|
(23,082,924)
|
Impairment loss on
inventories
|
|
|
—
|
|
(3,009,098)
|
|
(3,079,997)
|
|
(3,009,098)
|
Total Cost of
sales
|
|
|
(10,878,974)
|
|
(13,690,979)
|
|
(30,045,549)
|
|
(26,092,022)
|
Gross profit
(loss)
|
|
|
1,107,868
|
|
(1,172,348)
|
|
(1,786,479)
|
|
(3,494,882)
|
|
|
|
|
|
|
|
|
|
|
|
Research and
development expenses
|
|
|
(207,598)
|
|
(91,110)
|
|
(422,285)
|
|
(350,776)
|
Selling, general and
administrative expenses, net of subsidies
of nil and nil (2021 - $36,306 and
$100,605)
|
|
|
(15,907,638)
|
|
(15,447,682)
|
|
(26,461,372)
|
|
(31,462,316)
|
Impairment loss related
to property, plant and equipment
|
|
|
—
|
|
(1,884,970)
|
|
—
|
|
(2,414,702)
|
Impairment loss on
assets held for sale
|
|
|
(14,530,458)
|
|
—
|
|
(15,346,119)
|
|
—
|
Impairment loss related
to goodwill
|
|
|
(7,570,471)
|
|
—
|
|
(7,570,471)
|
|
—
|
Impairment loss related
to tradenames
|
|
|
(2,593,529)
|
|
—
|
|
(2,593,529)
|
|
—
|
Net gain on sale of
property, plant and equipment
|
|
|
—
|
|
—
|
|
85,002
|
|
—
|
Loss from operating
activities
|
|
|
(39,701,826)
|
|
(18,596,110)
|
|
(54,095,253)
|
|
(37,722,676)
|
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
|
|
16
|
|
4
|
|
1,440
|
|
7,343
|
Finance
costs
|
|
|
(379,007)
|
|
(458,786)
|
|
(1,295,529)
|
|
(816,902)
|
Loss on issuance of
derivatives
|
|
|
—
|
|
—
|
|
(2,126,955)
|
|
—
|
Foreign exchange
gains
|
|
|
4,613,545
|
|
1,501,869
|
|
6,020,830
|
|
214,482
|
Change in revaluation
of marketable securities
|
|
|
—
|
|
(77,712)
|
|
—
|
|
(89,924)
|
Gain (loss) on
revaluation of derivatives
|
|
|
(1,807,890)
|
|
5,528,509
|
|
7,715,810
|
|
7,461,839
|
|
|
|
|
2,426,664
|
|
6,493,884
|
|
10,315,596
|
|
6,776,838
|
Loss before income
taxes
|
|
|
(37,275,162)
|
|
(12,102,226)
|
|
(43,779,657)
|
|
(30,945,838)
|
|
|
|
|
|
|
|
|
|
|
|
Income tax (recovery)
expense
|
|
|
(12,530)
|
|
154
|
|
(12,530)
|
|
(11,944)
|
Net loss
|
|
|
(37,287,692)
|
|
(12,102,072)
|
|
(43,792,187)
|
|
(30,957,782)
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive
loss
|
|
|
|
|
|
|
|
|
|
Net change in
unrealized foreign currency losses on
translation of net investments in foreign
operations
(tax effect of nil for all
periods)
|
|
|
(3,702,162)
|
|
(2,693,068)
|
|
(6,493,641)
|
|
(716,506)
|
Total other
comprehensive loss
|
|
|
(3,702,162)
|
|
(2,693,068)
|
|
(6,493,641)
|
|
(716,506)
|
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive
loss
|
|
|
$(40,989,854)
|
|
$(14,795,140)
|
|
$(50,285,828)
|
|
$(31,674,288)
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable
to:
|
|
|
|
|
|
|
|
|
|
Equity holders of the
Company
|
|
|
$(30,897,458)
|
|
$(11,112,863)
|
|
$(35,181,808)
|
|
$(28,020,491)
|
Non-controlling
interest
|
|
|
(6,390,234)
|
|
(989,209)
|
|
(8,610,379)
|
|
(2,937,291)
|
Net loss
|
|
|
$(37,287,692)
|
|
$(12,102,072)
|
|
$(43,792,187)
|
|
$(30,957,782)
|
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive
loss attributable to:
|
|
|
|
|
|
|
|
|
|
Equity holders of the
Company
|
|
|
$(34,599,620)
|
|
$(13,805,931)
|
|
$(41,675,449)
|
|
$(28,736,997)
|
Non-controlling
interest
|
|
|
(6,390,234)
|
|
(989,209)
|
|
(8,610,379)
|
|
(2,937,291)
|
Total comprehensive
loss
|
|
|
$(40,989,854)
|
|
$(14,795,140)
|
|
$(50,285,828)
|
|
$(31,674,288)
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted loss
per share attributable to:
|
|
|
|
|
|
|
|
|
|
Equity holders of the
Company
|
|
|
$(3.94)
|
|
$(2.33)
|
|
$(5.03)
|
|
$(5.89)
|
Non-controlling
interest
|
|
|
$(0.81)
|
|
$(0.21)
|
|
$(1.23)
|
|
$(0.62)
|
Total loss per
share
|
|
|
$(4.75)
|
|
$(2.54)
|
|
$(6.26)
|
|
$(6.51)
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted
weighted average number of common shares
|
|
|
7,842,731
|
|
4,776,381
|
|
6,996,916
|
|
4,760,620
|
For the three and
sx-month periods ended September 30, 2022 and 2021
|
NEPTUNE WELLNESS SOLUTIONS INC.
Condensed Consolidated Interim Statements of Cash
Flows
(Unaudited) (in U.S.
dollars)
For the three and six-month periods ended
September 30, 2022 and
2021
|
|
|
|
|
|
|
Six-month periods
ended
|
|
|
|
September 30,
2022
|
|
September 30,
2021
|
|
|
|
|
|
|
Cash flows from
operating activities:
|
|
|
|
|
|
Net loss for the
period
|
|
|
$(43,792,187)
|
|
$(30,957,782)
|
Adjustments:
|
|
|
|
|
|
Depreciation of
property, plant and equipment
|
|
|
462,193
|
|
1,411,846
|
Non-cash lease
expense
|
|
|
314,900
|
|
432,742
|
Amortization of
intangible assets
|
|
|
952,057
|
|
1,775,889
|
Impairment loss on
goodwill
|
|
|
7,570,471
|
|
—
|
Impairment loss on
tradenames
|
|
|
2,593,529
|
|
—
|
Share-based
payment
|
|
|
1,826,983
|
|
5,237,918
|
Impairment loss on
inventories
|
|
|
3,079,997
|
|
3,009,098
|
Expected credit
losses
|
|
|
133,685
|
|
1,987,134
|
Non-employee
compensation related to warrants
|
|
|
—
|
|
153,650
|
Loss on issuance of
derivatives
|
|
|
2,126,955
|
|
—
|
Net finance
expense
|
|
|
1,294,089
|
|
809,559
|
Unrealized foreign
exchange (gain) loss
|
|
|
(6,020,830)
|
|
486,852
|
Change in revaluation
of marketable securities
|
|
|
—
|
|
89,924
|
Interest
received
|
|
|
1,440
|
|
7,167
|
Interest
paid
|
|
|
(44,784)
|
|
(391,022)
|
Revaluation of
derivatives
|
|
|
(7,715,810)
|
|
(7,461,839)
|
Impairment loss on
property, plant and equipment
|
|
|
—
|
|
2,414,702
|
Impairment loss on
assets held for sale
|
|
|
15,346,119
|
|
—
|
Payment of lease
liabilities
|
|
|
(227,107)
|
|
(145,138)
|
Income tax
expense
|
|
|
12,530
|
|
11,944
|
Net gains from sale of
property, plant and equipment
|
|
|
(85,002)
|
|
—
|
Changes in operating
assets and liabilities
|
|
|
8,087,556
|
|
(12,426,342)
|
Income taxes
paid
|
|
|
(360)
|
|
(11,944)
|
Net cash used in
operating activities
|
|
|
(14,083,576)
|
|
(33,565,642)
|
Cash flows from
investing activities:
|
|
|
|
|
|
Acquisition of
property, plant and equipment
|
|
|
(601,743)
|
|
(524,844)
|
Acquisition of
intangible assets
|
|
|
—
|
|
(436,018)
|
Net cash used in
investing activities:
|
|
|
(601,743)
|
|
(960,862)
|
Cash flows from
financing activities:
|
|
|
|
|
|
Increase in loans and
borrowings, net of financing fees
|
|
|
3,250,000
|
|
—
|
Proceeds from sale of
property, plant and equipment
|
|
|
85,002
|
|
—
|
Withholding taxes paid
pursuant to the settlement of non-treasury
RSUs
|
|
|
(260,034)
|
|
(978,117)
|
Gross proceeds from
the issuance of shares and warrants through a Direct
Offering
|
|
|
5,000,002
|
|
—
|
Issuance of shares and
warrants costs
|
|
|
(465,211)
|
|
—
|
Proceeds from exercise
of options and pre-funded warrants
|
|
|
65
|
|
—
|
Net cash provided by
(used in) financing activities:
|
|
|
7,609,824
|
|
(978,117)
|
Foreign exchange loss
on cash and cash equivalents
|
|
|
(256,243)
|
|
(13,054)
|
Net decrease in cash
and cash equivalents
|
|
|
(7,331,738)
|
|
(35,517,675)
|
Cash and cash
equivalents, beginning of period
|
|
|
8,726,341
|
|
59,836,889
|
Cash and cash
equivalents as at September 30, 2022 and 2021
|
|
|
$1,394,603
|
|
$24,319,214
|
|
|
|
|
|
|
Cash and cash equivalents is comprised
of:
|
|
|
|
|
|
Cash
|
|
|
$1,394,603
|
|
$24,319,214
|
NEPTUNE WELLNESS SOLUTIONS INC.
Condensed Consolidated Interim Statements of Cash Flows
(continued)
(Unaudited) (in U.S.
dollars)
For the three and six-month periods ended
September 30, 2022 and
2021
Supplemental cash flow disclosure:
Changes in operating assets and liabilities:
|
|
Six-month periods
ended
|
|
|
September 30,
2022
|
|
September 30,
2021
|
|
|
|
|
|
Trade and other
receivables
|
|
$2,519,493
|
|
$(2,749,349)
|
Prepaid
expenses
|
|
1,107,312
|
|
(465,022)
|
Inventories
|
|
(1,829,027)
|
|
(1,188,778)
|
Trade and other
payables
|
|
1,766,915
|
|
(7,067,094)
|
Deferred
revenues
|
|
(154,540)
|
|
452,621
|
Provisions
|
|
4,742,091
|
|
(1,256,033)
|
Other
liabilities
|
|
(64,688)
|
|
(152,687)
|
Changes in operating
assets and liabilities
|
|
$8,087,556
|
|
$(12,426,342)
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neptune-reports-fiscal-second-quarter-2023-financial-results-301705484.html
SOURCE Neptune Wellness Solutions Inc.